Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential first-line therapy in metastatic colorectal cancer with capecitabine/5-fluorouracil, irinotecan, and bevacizumab
2009-013099-38Phase 3Completed
- Sponsor
- LMU Klinikum
- Start
- Jun 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, irinotecan, capecitabine, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by LMU Klinikum. Primary endpoint: Time to failure of treatment strategy (TFS). Started Jun 2010; status: completed.
02
Drugs
bevacizumabirinotecancapecitabinefluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-013099-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013099-38.